Cadeler A/S
CDLRCadeler A/S is coiled. The quarters are improving, yet the P/E sits at the 15th percentile of its own 3-year range — the business is moving before the market.
The sharpest disagreement: annual EPS moved +315.8% against a +10.8% price move — the market has not yet caught up with the delivery.
The price is in a confirmed uptrend (4 weeks in) while the P/E sits at the 15th percentile of its own 3-year range. Underneath, the last four quarters read improving, and 150% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Cadeler A/S trades at $22.7, in a confirmed uptrend and 4 weeks into that stage. That is +0.4% against its own 200-day average. It sits at 50% of a 52-week range of $16 to $30. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (12 weeks and counting).
Today the stock is in a confirmed uptrend — week 4 of stage 2. At $22.7 it trades +0.4% versus its 200-day average and sits at 50% of its 52-week range ($16–$30).
Against the market, two honest reads. Cumulative: over the last 2.6 years the stock moved +25% while the S&P 500 moved +63% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (12 weeks and counting; last ahead the week of 2026-05-15) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Cadeler A/S trades at 7.0× P/E, near the bottom of its own range — cheaper only 15% of the time. Its long-run median P/E is 17.8×, measured across 2.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 7.0× is near the bottom of its own range — cheaper only 15% of the time, against a long-run median of 17.8× measured over 2.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.
Why the multiple sits where it does: over the past year annual EPS moved +315.8% against a +10.8% price move — earnings outran the price, pushing the multiple DOWN its own range.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Cadeler A/S reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: revenue growth has eased from +200.0% at its peak to +123.3% but is still expanding, ROCE holding at 11.7%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +148.0% | +78.0% | — | — |
| Profit | +300.0% | +91.3% | — | — |
| EPS | +315.8% | +53.1% | — | — |
| Stock price | +10.8% | — | — | — |
4-Factor Sector Score
48.8/100 — rank 14 of 30 in Engineering & Construction · 66% evidence confidence
Cadeler A/S scores 48.8 out of 100 against the 30 companies it is compared with in Engineering & Construction, ranking 14. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 19.7 + 7.7 + 16.5 + 4.9 = 48.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Cadeler A/S reported $0.1 B of revenue in the Mar 26 quarter, +71.4% year on year. That is the 8th straight quarter of year-on-year growth. Over 4 years it has compounded at 79.3% a year. The last full year, FY25, came in at $0.6 B. The last four reported quarters add to $0.7 B.
FY25 revenue came in at $0.6 B (+148.0% on the year), capping 4 years at 79.3% compound. The latest quarter (Mar 26) printed $0.1 B, +71.4% year on year — the 8th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +132.8% growth against the decade's 79.3% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +123.3% over the last 4 quarters against +146.8%/yr over the last 8 — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Cadeler A/S's operating margin is 8.3% in the Mar 26 quarter, +8.3 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged 9.1% to 51.6%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 8.3%, +8.3 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 9.1%–51.6%, and FY25's 51.6% is the top of that band — a record year.
Why the margin moved: operating margin went +8.3 pp year on year while gross margin went −3.6 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Cadeler A/S posted a net loss of $0.01 B in the Mar 26 quarter. Full-year FY25 profit was $0.3 B. The 4-year compound rate is 130.0%. That loss is 8.3% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 3 of the last 12 reported quarters were loss-making.
Mar 26 profit was $−0.0 B, null year on year. On the full year, FY25 printed $0.3 B (+300.0%), and the 4-year compound rate is 130.0%.
Pace comparison, last four quarters: profit +291.7% vs revenue +132.8%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 150% of Cadeler A/S's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.4 B of operating cash against $0.3 B of profit. After $1.2 B of capital spending, $−0.8 B was left as free cash.
FY25: operating cash of $0.4 B against reported profit of $0.3 B, leaving free cash of $−0.8 B after $1.2 B of capital spending. Across the last 3 fiscal years the conversion rate is 150% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Cadeler A/S does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $2.0 B over the last 3 years. Averaged over those years that is 107.5% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $2.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Cadeler A/S earns a ROE of 19% in FY25. That is up from a trough of 3% in FY21. Return on invested capital clears the cost of that capital by +4.7 percentage points, so growth here adds value rather than only size. The wiring behind it is 45.2% net margin on 0.18× asset turns.
FY25 ROE is 19%, recovered from a FY21 trough of 3% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 45.2% net margin × 0.18× asset turns × 2.28× balance-sheet leverage ≈ 18.6% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 10.4% − 5.7% = a +4.7 pp spread. The 5.7% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Dividend
Cadeler A/S pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Cadeler A/S does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Cadeler A/S carries total debt of $1.6 B against shareholder equity of $1.7 B as of Mar 26, a debt-to-equity of 0.95. On the annual view that ratio went from 0.21 in FY21 to 1.08 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $1.6 B against shareholder equity of $1.7 B — a debt-to-equity of 0.95. On the annual view, debt-to-equity went from 0.21 (FY21) to 1.08 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
No ownership or positioning reading is held for Cadeler A/S, so this section names the gap rather than filling it. At typical trading volumes those positions would take about 9.4 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
We hold no ownership or positioning reading for this stock, so this section says that plainly.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Cadeler A/S: the Z-score reads 1.17. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
🚨 Why it matters: a Z-score of 1.17 is inside the distress zone — the balance sheet is a real risk, not a detail.
The safety line in one sentence: the Z-score reads 1.17.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Argan, Inc.AGX | 69.3/100Favorable setup81% evidence | ASLEEP | 26.6/35 Revenue 14.5% · PAT 61% · OPM change 3 pp 83% evidence | 16.1/25 ROCE 10.5% · OPM 15.6% 76% evidence | 12.3/20 P/E 58.9× · PEG 0.99 65% evidence | 14.3/20 RS sector 24.9% · RS bench 25.1% · 1Y 158.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 26.6 + 16.1 + 12.3 + 14.3 = 69.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Comfort Systems USA, Inc.FIX | 66.8/100Thin evidence · provisional56% evidence | ASLEEP | 23.6/35 Revenue — · PAT — · OPM change 5.6 pp 39% evidence | 20.1/25 ROCE 18.3% · OPM 17% 76% evidence | 9.3/20 P/E 48.8× · PEG — 15% evidence | 13.8/20 RS sector 24.3% · RS bench 25% · 1Y 156.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 23.6 + 20.1 + 9.3 + 13.8 = 66.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3IES Holdings, Inc.IESC | 65.9/100Thin evidence · provisional53% evidence | LEADER | 19.7/35 Revenue — · PAT — · OPM change 1.2 pp 32% evidence | 17.1/25 ROCE 15.8% · OPM 11.2% 76% evidence | 10.2/20 P/E 32.6× · PEG — 15% evidence | 18.9/20 RS sector 36% · RS bench 37.9% · 1Y 119.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 17.1 + 10.2 + 18.9 = 65.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Everus Construction Group, Inc.ECG | 64.6/100Mixed-positive evidence66% evidence | ASLEEP | 22.5/35 Revenue 29.7% · PAT 46.7% · OPM change 1.3 pp 53% evidence | 13.8/25 ROCE 8.4% · OPM 7.5% 57% evidence | 15.2/20 P/E 27.1× · PEG 0.58 65% evidence | 13.1/20 RS sector 10.4% · RS bench 11.9% · 1Y 90.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 13.8 + 15.2 + 13.1 = 64.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Sterling Infrastructure, Inc.STRL | 62.8/100Mixed-positive evidence66% evidence | FADING | 24.3/35 Revenue 36.9% · PAT 32.5% · OPM change 3.7 pp 53% evidence | 15.4/25 ROCE 9.3% · OPM 16.7% 57% evidence | 11.8/20 P/E 36.4× · PEG 1.19 65% evidence | 11.3/20 RS sector 4.4% · RS bench 5.1% · 1Y 78.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.3 + 15.4 + 11.8 + 11.3 = 62.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Dycom Industries, Inc.DY | 57.5/100Mixed-positive evidence81% evidence | ASLEEP | 22.2/35 Revenue 29.8% · PAT 34.2% · OPM change 0.5 pp 83% evidence | 11.9/25 ROCE 3.8% · OPM 7.3% 76% evidence | 11.1/20 P/E 41.3× · PEG 1.24 65% evidence | 12.3/20 RS sector 1.1% · RS bench 2.9% · 1Y 48.7%6 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 11.9 + 11.1 + 12.3 = 57.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7EMCOR Group, Inc.EME | 56.8/100Thin evidence · provisional56% evidence | ASLEEP | 19.6/35 Revenue — · PAT — · OPM change 0.5 pp 39% evidence | 16.4/25 ROCE 12.2% · OPM 8.7% 76% evidence | 10.7/20 P/E 25.8× · PEG — 15% evidence | 10.1/20 RS sector -0.3% · RS bench 1.9% · 1Y 32.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 16.4 + 10.7 + 10.1 = 56.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8MYR Group Inc.MYRG | 56.3/100Thin evidence · provisional56% evidence | FADING | 21.9/35 Revenue — · PAT — · OPM change 2.4 pp 39% evidence | 12.6/25 ROCE 7.9% · OPM 6.5% 76% evidence | 9.5/20 P/E 47.5× · PEG — 15% evidence | 12.3/20 RS sector 5.8% · RS bench 6.6% · 1Y 83.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 12.6 + 9.5 + 12.3 = 56.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Arcosa, Inc.ACA | 55.2/100Mixed-positive evidence66% evidence | BREAKING OUT | 19.6/35 Revenue 12.1% · PAT 100% · OPM change 0.7 pp 53% evidence | 9.3/25 ROCE 1.1% · OPM 8.2% 57% evidence | 8.5/20 P/E 23.4× · PEG 2.09 65% evidence | 17.8/20 RS sector 12% · RS bench 14.7% · 1Y 51.4%10 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 9.3 + 8.5 + 17.8 = 55.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Tetra Tech, Inc.TTEK | 55.2/100Thin evidence · provisional56% evidence | TURNING | 19.1/35 Revenue — · PAT — · OPM change 7.8 pp 39% evidence | 13.9/25 ROCE 5.2% · OPM 10.8% 76% evidence | 11.3/20 P/E 17.6× · PEG — 15% evidence | 10.9/20 RS sector -8.7% · RS bench -5.4% · 1Y -5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 13.9 + 11.3 + 10.9 = 55.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Quanta Services, Inc.PWR | 54.8/100Thin evidence · provisional56% evidence | ASLEEP | 19.9/35 Revenue — · PAT — · OPM change 0.5 pp 39% evidence | 11.6/25 ROCE 4.4% · OPM 4.3% 76% evidence | 8.8/20 P/E 82.5× · PEG — 15% evidence | 14.5/20 RS sector 15.7% · RS bench 17.3% · 1Y 79.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 19.9 + 11.6 + 8.8 + 14.5 = 54.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Exponent, Inc.EXPO | 51.5/100Thin evidence · provisional56% evidence | TURNING | 17.8/35 Revenue — · PAT — · OPM change -5.6 pp 39% evidence | 15.0/25 ROCE 5% · OPM 24.9% 76% evidence | 10.5/20 P/E 27.3× · PEG — 15% evidence | 8.2/20 RS sector -13.2% · RS bench -10.1% · 1Y -4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17.8 + 15 + 10.5 + 8.2 = 51.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Tutor Perini CorporationTPC | 49.6/100Thin evidence · provisional51% evidence | ASLEEP | 16.5/35 Revenue 25.6% · PAT — · OPM change -0.9 pp 40% evidence | 8.2/25 ROCE 3.2% · OPM 4.3% 57% evidence | 9.2/20 P/E 52.5× · PEG — 15% evidence | 15.7/20 RS sector 3.6% · RS bench 6% · 1Y 51.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 8.2 + 9.2 + 15.7 = 49.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Cadeler A/Sthis pageCDLR | 48.8/100Mixed-negative evidence66% evidence | ASLEEP | 19.7/35 Revenue 100% · PAT 100% · OPM change -1.2 pp 53% evidence | 7.7/25 ROCE 0.3% · OPM 6.2% 57% evidence | 16.5/20 P/E 6.6× · PEG 0.11 65% evidence | 4.9/20 RS sector -10.4% · RS bench -8.4% · 1Y 8.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 7.7 + 16.5 + 4.9 = 48.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Stantec Inc.STN | 47.1/100Mixed-negative evidence66% evidence | BASING | 17.6/35 Revenue 7.6% · PAT 27.6% · OPM change 0.4 pp 53% evidence | 11.4/25 ROCE 3.1% · OPM 8.3% 57% evidence | 13.1/20 P/E 28× · PEG 1.01 65% evidence | 5.0/20 RS sector -32.4% · RS bench -29.6% · 1Y -33.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 11.4 + 13.1 + 5 = 47.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16AECOMACM | 44.9/100Mixed-negative evidence66% evidence | BASING | 12.8/35 Revenue -0.4% · PAT 2.6% · OPM change -0.3 pp 53% evidence | 11.4/25 ROCE 4.2% · OPM 6.5% 57% evidence | 15.3/20 P/E 22.1× · PEG 0.73 65% evidence | 5.4/20 RS sector -33.9% · RS bench -30.7% · 1Y -36%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.8 + 11.4 + 15.3 + 5.4 = 44.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 17APi Group CorporationAPG | 44.7/100Thin evidence · provisional56% evidence | ASLEEP | 18.0/35 Revenue — · PAT — · OPM change 0.3 pp 39% evidence | 8.9/25 ROCE 2.5% · OPM 5.2% 76% evidence | 8.7/20 P/E 95.5× · PEG — 15% evidence | 9.1/20 RS sector -9.1% · RS bench -6.8% · 1Y 20.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 8.9 + 8.7 + 9.1 = 44.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Fluor CorporationFLR | 43.3/100Thin evidence · provisional56% evidence | TURNING | 11.8/35 Revenue -8.3% · PAT -422.2% · OPM change 0.2 pp 53% evidence | 7.4/25 ROCE 1.8% · OPM 2.5% 57% evidence | 10.8/20 P/E 25.4× · PEG — 15% evidence | 13.3/20 RS sector -2.1% · RS bench 0.5% · 1Y 23%2 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 7.4 + 10.8 + 13.3 = 43.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19KBR, Inc.KBR | 43.1/100Thin evidence · provisional56% evidence | TURNING | 14.1/35 Revenue — · PAT — · OPM change -0.6 pp 39% evidence | 10.3/25 ROCE 3.5% · OPM 9.4% 76% evidence | 11.4/20 P/E 10.9× · PEG — 15% evidence | 7.3/20 RS sector -20% · RS bench -16.8% · 1Y -24.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 10.3 + 11.4 + 7.3 = 43.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Granite Construction IncorporatedGVA | 42.8/100Thin evidence · provisional56% evidence | ASLEEP | 18.8/35 Revenue — · PAT — · OPM change 2.3 pp 39% evidence | 9.2/25 ROCE 5.8% · OPM -3.4% 76% evidence | 10.1/20 P/E 34.5× · PEG — 15% evidence | 4.7/20 RS sector -11.4% · RS bench -9.3% · 1Y 15.2%3 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 9.2 + 10.1 + 4.7 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21MasTec, Inc.MTZ | 40.3/100Thin evidence · provisional56% evidence | ASLEEP | 19.8/35 Revenue — · PAT — · OPM change 2.4 pp 39% evidence | 8.4/25 ROCE 3.4% · OPM 3.7% 76% evidence | 9.0/20 P/E 66.4× · PEG — 15% evidence | 3.1/20 RS sector -12% · RS bench -11.1% · 1Y 49.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 8.4 + 9 + 3.1 = 40.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Construction Partners, Inc.ROAD | 39.3/100Mixed-negative evidence66% evidence | BASING | 19.8/35 Revenue 48.7% · PAT 100% · OPM change 0.1 pp 53% evidence | 8.3/25 ROCE 1.5% · OPM 4.9% 57% evidence | 8.2/20 P/E 48.7× · PEG 1.79 65% evidence | 3.0/20 RS sector -20% · RS bench -17.5% · 1Y -4.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 8.3 + 8.2 + 3 = 39.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Ameresco, Inc.AMRC | 37.0/100Thin evidence · provisional55% evidence | ASLEEP | 14.5/35 Revenue 8.5% · PAT -9.3% · OPM change -1.3 pp 40% evidence | 7.2/25 ROCE 0.3% · OPM 2.6% 57% evidence | 9.9/20 P/E 44× · PEG 1.49 65% evidence | 5.4/20 RS sector -19.2% · RS bench -16.4% · 1Y 38.9%1 of 12 weeks ahead 70% evidence |
| Exact sum: 14.5 + 7.2 + 9.9 + 5.4 = 37 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24Jacobs Solutions Inc.J | 35.2/100Mixed-negative evidence66% evidence | TURNING | 11.3/35 Revenue 12.7% · PAT -9.3% · OPM change -9.4 pp 53% evidence | 6.8/25 ROCE -1% · OPM -2.2% 57% evidence | 6.9/20 P/E 38.7× · PEG 2.2 65% evidence | 10.2/20 RS sector -9.7% · RS bench -6.3% · 1Y -3.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 11.3 + 6.8 + 6.9 + 10.2 = 35.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25TopBuild Corp.BLD | 35.2/100Thin evidence · provisional60% evidence | 11.8/35 Revenue 6.4% · PAT -15.2% · OPM change -2.3 pp 53% evidence | 12.8/25 ROCE 3.6% · OPM 12.1% 57% evidence | 6.3/20 P/E 19.7× · PEG 2.97 65% evidence | 4.3/20 RS sector -30% · RS bench -23.4% · 1Y 2%2 of 7 weeks ahead to 2026-07-02 70% evidence | |
| Exact sum: 11.8 + 12.8 + 6.3 + 4.3 = 35.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Primoris Services CorporationPRIM | 34.3/100Adverse evidence66% evidence | BASING | 13.9/35 Revenue 13.4% · PAT 20.4% · OPM change -2.7 pp 53% evidence | 7.9/25 ROCE 1% · OPM 1.6% 57% evidence | 10.0/20 P/E 31.5× · PEG 1.57 65% evidence | 2.5/20 RS sector -38.4% · RS bench -36.6% · 1Y -18.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 7.9 + 10 + 2.5 = 34.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Cardinal Infrastructure Group Inc.CDNL | 50.6/100Thin evidence · provisional22% evidence | BREAKING OUT | 18.6/35 Revenue — · PAT — · OPM change -0.9 pp 15% evidence | 13.5/25 ROCE 5.6% · OPM 8.8% 57% evidence | 8.5/20 P/E 403× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 18.6 + 13.5 + 8.5 + 10 = 50.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Ferrovial N.V.FER | 44.7/100Thin evidence · provisional43% evidence | ASLEEP | 18.0/35 Revenue — · PAT — · OPM change — 12% evidence | 9.8/25 ROCE 1.3% · OPM — 61% evidence | 8.9/20 P/E 71.4× · PEG — 15% evidence | 8.0/20 RS sector -10.6% · RS bench -8.2% · 1Y 26.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 9.8 + 8.9 + 8 = 44.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Legence Corp.LGN | 40.8/100Thin evidence · provisional31% evidence | ASLEEP | 15.7/35 Revenue 44.3% · PAT 13.3% · OPM change -1.1 pp 40% evidence | 6.5/25 ROCE 1.1% · OPM 2.2% 57% evidence | 8.6/20 P/E 192.6× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 12 weeks ahead 0% evidence |
| Exact sum: 15.7 + 6.5 + 8.6 + 10 = 40.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Willdan Group, Inc.WLDN | 37.7/100Thin evidence · provisional50% evidence | BASING | 15.4/35 Revenue — · PAT — · OPM change 0.1 pp 39% evidence | 7.2/25 ROCE 2% · OPM 4.7% 76% evidence | 11.1/20 P/E 21.7× · PEG — 15% evidence | 4.0/20 RS sector -30.8% · RS bench -28.1% · 1Y -32.7%2 of 12 weeks ahead 70% evidence |
| Exact sum: 15.4 + 7.2 + 11.1 + 4 = 37.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Cadeler A/S's stock price today?
Cadeler A/S trades at $22.7, +10.8% over the past year. The company is valued at $2.0 B. The stock sits at 50% of its 52-week range of $16–$30, +0.4% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 4 weeks in. — as of 5 August 2026.
What were Cadeler A/S's latest quarterly results?
Cadeler A/S reported revenue of $0.1 B and a net loss of $0.0 B for the Mar 26 quarter. Earnings per share were $−0.08. The operating margin was 8.3%, 8.3 pp higher than a year earlier. — as of 5 August 2026.
What is Cadeler A/S's revenue?
Cadeler A/S reported revenue of $0.1 B in the Mar 26 quarter, +71.4% year on year. For the full FY25 fiscal year, revenue was $0.6 B (+148.0%). Over the last 4 years revenue compounded at 79.3% a year. — as of 5 August 2026.
What is Cadeler A/S's profit?
Cadeler A/S earned $−0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.3 B. The operating margin ran 8.3% in the latest quarter. — as of 5 August 2026.
What is Cadeler A/S's market cap?
Cadeler A/S's market capitalisation is $2.0 B at a stock price of $22.7. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is Cadeler A/S's P/E ratio?
Cadeler A/S trades at a P/E of 7.0×, at the 15th percentile of its own 3-year range, against a long-run median of 17.8×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does Cadeler A/S pay a dividend?
No — Cadeler A/S has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
Is Cadeler A/S overvalued?
On its own history, Cadeler A/S looks cheap against its own history: its P/E of 7.0× has been cheaper only 15% of the time in 3 years (long-run median 17.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 5 August 2026.
How is Cadeler A/S performing?
Cadeler A/S is in a confirmed uptrend, 4 weeks in. Against the S&P 500 it has been behind on a trailing-13-week view for 12 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Cadeler A/S in?
Mixed — growth is normalizing off a hyper-growth base: revenue growth has eased from +200.0% at its peak to +123.3% but is still expanding, ROCE holding at 11.7%. The read comes from the last 12 quarters of growth (revenue growth +123.3% latest, profit growth +200.0% latest, eps growth +201.8% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Cadeler A/S in an uptrend?
Yes — the price is in a confirmed uptrend (week 4 of stage 2), trading +0.4% versus its 200-day average and at 50% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Cadeler A/S beating the market?
Not lately — on a trailing-13-week view Cadeler A/S is currently behind the S&P 500 (12 weeks and counting; last ahead the week of 2026-05-15), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 2.6 years the stock moved +25% against the S&P 500's +63% — behind the index over the full window. — as of 5 August 2026.
Will Cadeler A/S's stock price go up?
This page publishes no price forecast for Cadeler A/S. What it measures instead: the stock price is $22.7, the price is in a confirmed uptrend 4 weeks in. Its P/E of 7.0× sits at the 15th percentile of its own 3-year range. — as of 5 August 2026.
Does Cadeler A/S have too much debt?
It is moderate — Cadeler A/S's debt-to-equity is 0.95. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is Cadeler A/S's capex?
Cadeler A/S spent $2.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $1.2 B. — as of 5 August 2026.
What is Cadeler A/S's cash flow?
Cadeler A/S generated $0.4 B of operating cash flow in FY25 and $−0.8 B of free cash flow after $1.2 B of capital spending. Reported profit that year was $0.3 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Cadeler A/S's profit real cash?
Yes — over the last 3 fiscal years, 150% of Cadeler A/S's reported profit arrived as operating cash. In FY25, operating cash was $0.4 B against reported profit of $0.3 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Cadeler A/S?
On the balance sheet, the Z-score reads 1.17 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is inside the danger band — a real balance-sheet risk. — as of 5 August 2026.
Where is Cadeler A/S in its business cycle?
Cadeler A/S's FY25 operating margin was 51.6%, against a 5-year band of 9.1%–51.6%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 8.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Cadeler A/S story?
The sharpest disagreement: annual EPS moved +315.8% against a +10.8% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Cadeler A/S a stock worth studying right now?
This is not investment advice. The machine read: Cadeler A/S is coiled. The quarters are improving, yet the P/E sits at the 15th percentile of its own 3-year range — the business is moving before the market. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.